Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | ECE1 | P42892 | 4/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21879060 | 1.00 | KDM4E (0.66) | KDM4EPOLBP2RY14TP53ACE | |
| SCHEMBL21879116 | 0.96 | LTA4H (0.63) | KDM4EPOLBP2RY14TP53ACE | |
| SCHEMBL21879133 | 0.96 | POLB (0.70) | KDM4EPOLBP2RY14TP53ACE | |
| SCHEMBL21937712 | 0.89 | MAPT (0.67) | KDM4ETP53MEN1KMT2AMAPT | |
| SCHEMBL30127790 | 0.89 | MAPT (0.67) | KDM4ETP53MEN1KMT2AMAPT | |
| SCHEMBL26447749 | 0.89 | MAPT (0.67) | KDM4ETP53MEN1KMT2AMAPT | |
| SCHEMBL12569733 | 0.88 | MMP9 (0.64) | POLBP2RY14TP53 | |
| SCHEMBL30051742 | 0.88 | ACE (0.68) | P2RY14ACEECE1ERAP2LTA4H | |
| SCHEMBL21937714 | 0.87 | MAPT (0.61) | KDM4ETP53MEN1KMT2AMAPT | |
| SCHEMBL30127739 | 0.87 | MAPT (0.61) | KDM4ETP53MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081692-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230132854-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20200131218-A1 | MITHRAMYCIN OXIME AND HYDRAZINE DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132854-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | TFAM, HSPE1, PRDX3 | KDM4E 1642/4885POLB 741/4885P2RY14 4746/4885 |
| US-20200131218-A1 | MITHRAMYCIN OXIME AND HYDRAZINE DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | HMOX1, HSPE1, TFAM | KDM4E 1638/4885POLB 1379/4885P2RY14 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.